Salivary Gland Neoplasms - 16 Studies Found

Recruiting : Activity of Sorafenib in Salivary Gland Cancer
: Salivary Gland Cancer
: 2012-04-06
: Drug: Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
Active, not recruiting : Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
:
  • Recurrent Salivary Gland Cancer
  • Stage IVA Salivary Gland Cancer
  • Major Salivary Gland Carcinoma
  • Minor Salivary Gland Carcinoma
  • Biological: Ipilimumab Given I
Active, not recruiting : Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
: Salivary Gland Carcinoma
: 2015-03-13
: Drug: pazopanib treatment will be given until progression or unacceptable toxicity .
<<< Previous